
|Videos|November 12, 2021
ImprimisRx President John Saharek discusses 3 new products in the pipeline
Author(s)David Hutton, Modern Retina Staff
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
Advertisement
John Saharek, president of ImprimisRX, speaks with Modern Retina's David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting, including:
- Moxi-Brom (moxifloxacin hydrochloride 0.5% and bromfenac sodium sesquihydrate 0.075%)
- Klarity-CL drops (cyclosporine 0.1% / loteprednol etabonate 0.2% ophthalmic suspension)
- Tim-Brim-Dor-Bim (prednisolone acetate 1%, gatifloxacin 0.5%, bromfenac 0.075%).
The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.
Related Content:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Altered ipRGC circuits and function may translate to disrupted sleep and circadian rhythms in Alzheimer’s disease
2
StemSight gains patent for off-the-shelf limbal stem cell platform patent milestone for STE-101
3
CTS 2026: OTX-TKI demonstrates superiority over aflibercept in wet AMD—what the SOL-1 data mean for retina practice
4
Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidence
5




















